Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 2/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 7/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | SMO | Q99835 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | WEE1 | P30291 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319726 | 0.92 | CDC7 (0.45) | MAPKAPK2CDC7GRM4KDREGFR | |
| SCHEMBL6321411 | 0.89 | NPC1 (0.49) | GRM4EGFRCLK2CLK3DYRK1A | |
| SCHEMBL6313590 | 0.89 | CDC7 (0.47) | MAPKAPK2CDC7KDREGFRCLK2 | |
| SCHEMBL6315305 | 0.84 | DYRK1A (0.45) | GRM4EGFRCLK2CLK3DYRK1A | |
| SCHEMBL6312020 | 0.83 | SYK (0.47) | GRM4EGFRCLK2CLK3DYRK1A | |
| SCHEMBL6311247 | 0.83 | CDK1 (0.50) | CLK2CLK3DYRK1ASYK | |
| SCHEMBL6311534 | 0.82 | NPC1 (0.46) | GRM4KDREGFRCLK2CLK3 | |
| SCHEMBL6312651 | 0.81 | CDC7 (0.47) | MAPKAPK2CDC7KDREGFRCLK2 | |
| SCHEMBL6314056 | 0.79 | IGF1R (0.52) | KDRCLK2CLK3DYRK1APTK2 | |
| SCHEMBL6319822 | 0.78 | IGF1R (0.50) | KDRCLK2CLK3DYRK1ASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | MAPKAPK2 4269/4885CDC7 2635/4885GRM4 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.